banner

News Releases

Date Title and Summary  
Toggle Summary ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
SAN DIEGO --(BUSINESS WIRE)--Dec. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Nov. 26, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
-Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder -FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID ® for Patients with
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
- Pimavanserin met primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to placebo (p=0.039) - Pimavanserin met key secondary endpoint with statistically significant overall improvement in Sheehan Disability Scale compared to placebo (p=0.004) -
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Executive Leadership Change
SAN DIEGO --(BUSINESS WIRE)--Oct. 29, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S. Young, Executive Vice President and Chief Financial Officer, will be leaving the organization effective October 31, 2018 to join another healthcare company.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, November 6, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 23, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
- Robert Kaper , M.D., named Senior Vice President, Global Head of Medical Affairs - Eliseo Salinas , M.D., M.Sc., named Senior Vice President, Chief Scientific Officer and Head of External Innovation SAN DIEGO --(BUSINESS WIRE)--Sep. 26, 2018-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
- FDA analysis finds no new or unexpected safety risks associated with NUPLAZID - Patients taking NUPLAZID for Parkinson’s disease psychosis should continue to use it as prescribed by their health care provider - FDA also reminds health care providers that no other antipsychotic medication is
Printer Friendly Version
Toggle Summary Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
– Second Quarter Net Sales Grew to $57.1 Million , Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 – Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID ® (Pimavanserin) – Expanded ACADIA’s Pipeline in Central Nervous System Disorders with Exclusive
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
- ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren retains all rights to trofinetide outside of North America -Neuren to receive US $10 million upfront plus potential
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
– New Dosing Formulation and Strength Address Needs in Treating Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Jun. 29, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
SAN DIEGO --(BUSINESS WIRE)--Jun. 13, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Jun. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN DIEGO --(BUSINESS WIRE)--May 8, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
– Strong Performance for NUPLAZID ® in First Quarter 2018 – First Quarter Net Sales Grew to $48.9 Million , Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17 – ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million SAN DIEGO --(BUSINESS WIRE)--May 4,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
SAN DIEGO --(BUSINESS WIRE)--May 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff ,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
ACADIA to Host Conference Call and Webcast on Friday, May 4, 2018 , at 8:30 a.m. Eastern Time SAN DIEGO, Calif. --(BUSINESS WIRE)--May 1, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
- Concurrently, the Company Has Issued a Press Release Announcing the Presentation of Clinical Experience Data for NUPLAZID at the American Academy of Neurology (AAN) Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
Two Independent Data Sets Confirm NUPLAZID Is Well-Tolerated and Efficacious in Treating Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the
Printer Friendly Version
Toggle Summary PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
Results underscore need for greater awareness of non-movement symptoms this Parkinson’s Disease Awareness Month TUCSON, Ariz. & SAN DIEGO --(BUSINESS WIRE)--Apr. 23, 2018-- As part of Parkinson’s Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
SAN DIEGO --(BUSINESS WIRE)--Mar. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Mar. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million , Respectively SAN DIEGO --(BUSINESS WIRE)--Feb. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, February 27, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
SAN DIEGO --(BUSINESS WIRE)--Jan. 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version